期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 114, 期 13, 页码 E2563-E2570出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1621513114
关键词
nuclear receptors; drug discovery; structure-based design; peroxisome roliferator-activated receptor; cation-pi interaction
资金
- National Science Foundation [EEC-0813570]
- NIH [DK057978, HL105278, DK090962, HL088093, ES010337, CA014195]
- Leona M. and Harry B. Helmsley Charitable Trust [2012-PG-MED-002]
The peroxisome proliferator-activated receptor (PPAR) family comprises three subtypes: PPAR alpha, PPAR gamma, and PPAR delta. PPAR delta transcriptionally modulates lipid metabolism and the control of energy homeostasis; therefore, PPAR delta agonists are promising agents for treating a variety of metabolic disorders. In the present study, we develop a panel of rationally designed PPAR delta agonists. The modularmotif affords efficient syntheses using building blocks optimized for interactions with subtype-specific residues in the PPARd ligand-binding domain (LBD). A combination of atomic-resolution protein X-ray crystallographic structures, ligand-dependent LBD stabilization assays, and cell-based transactivation measurements delineate structure-activity relationships (SARs) for PPAR delta-selective targeting and structural modulation. We identify key ligand-induced conformational transitions of a conserved tryptophan side chain in the LBD that trigger reorganization of the H2'-H3 surface segment of PPARd. The subtype-specific conservation of H2'-H3 sequences suggests that this architectural remodeling constitutes a previously unrecognized conformational switch accompanying ligand-dependent PPAR delta transcriptional regulation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据